



Criteria For A Recommended Standard

**Occupational Exposure to
Ethylene Glycol Monobutyl Ether
and
Ethylene Glycol Monobutyl Ether Acetate**



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Centers for Disease Control
National Institute for Occupational Safety and Health



CRITERIA FOR A RECOMMENDED STANDARD

Occupational Exposure to Ethylene Glycol Monobutyl Ether and Ethylene Glycol Monobutyl Ether Acetate

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Centers for Disease Control
National Institute for Occupational Safety and Health
Division of Standards Development and Technology Transfer
Cincinnati, Ohio

September 1990

DISCLAIMER

Mention of the name of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health.

This document is in the public domain and may be freely copied or reprinted. Copies of this and other NIOSH documents are available from

**Publications Dissemination, DSDTT
National Institute for Occupational Safety and Health
4676 Columbia Parkway
Cincinnati, Ohio 45226
(513) 533-8287**

**For information about other occupational safety and health problems, call
1-800-35-NIOSH**

DHHS (NIOSH) Publication No. 90-118


FOREWORD

In the Occupational Safety and Health Act of 1970 (Public Law 91-596), Congress declared that its purpose was to assure, insofar as possible, safe and healthful working conditions for every working man and woman and to preserve our human resources. The Act authorizes the National Institute for Occupational Safety and Health (NIOSH) to develop and establish recommended occupational safety and health standards and to develop criteria that will assure that no employee will suffer diminished health, functional capacity, or life expectancy as a result of his or her work experience. By means of criteria documents, NIOSH communicates these recommended standards to regulatory agencies (including the Occupational Safety and Health Administration [OSHA] and the Mine Safety and Health Administration [MSHA]) and to others in the community of occupational safety and health.

Criteria documents provide the scientific basis for new occupational safety and health standards. These documents generally contain a critical review of the scientific and technical information available on the prevalence of hazards, the existence of safety and health risks, and the adequacy of control methods. In addition to transmitting these documents to the Department of Labor, NIOSH also distributes them to health professionals in academic institutions, industry, organized labor, public interest groups, and other government agencies.

This criteria document reviews available information about the adverse health effects associated with exposure to ethylene glycol monobutyl ether (EGBE) and ethylene glycol monobutyl ether acetate (EGBEA). The results of studies in animals have clearly demonstrated dose-related adverse effects on the central nervous system, the hematopoietic tissues, the blood, the kidneys, and the liver in several species by different routes of administration. Limited data from humans also indicate the risk of adverse effects on the central nervous and hematopoietic tissues, the blood, and the kidneys. Because limited data are available from studies in humans, NIOSH bases its recommended exposure limits (RELs) for EGBE and EGBEA on data from studies in animals. The data were adjusted to allow for uncertainties in the extrapolation from animals to humans.

NIOSH takes sole responsibility for the conclusions and recommendations presented in this document. All reviewers' comments are being sent with this document to OSHA and MSHA for consideration in standard setting.



J. Donald Millar, M.D., D.T.P.H. (Lond.)
Assistant Surgeon General
Director, National Institute for
Occupational Safety and Health
Centers for Disease Control

ABSTRACT

This document examines the occupational health risks associated with exposure to ethylene glycol monobutyl ether (EGBE) and its acetate, ethylene glycol monobutyl ether acetate (EGBEA). Criteria are also provided for eliminating or minimizing the risks encountered by workers during the manufacture and use of EGBE and EGBEA. These criteria include recommendations for preventing dermal contact, sampling and analytical methods, medical monitoring, biological monitoring, engineering controls and work practices, and protective clothing and equipment.

In humans and animals, the principal health effects of exposure to EGBE and EGBEA involve the blood and hematopoietic system, the central nervous system (CNS), the kidneys, and the liver. No evidence indicates that EGBE or EGBEA causes reproductive or developmental toxicity.

In animals, CNS, liver, and kidney effects occur at higher EGBE exposures than hematotoxic effects. Thus limiting exposures to prevent hematotoxic effects will also prevent CNS, kidney, and liver effects. Because limited data are available from studies in humans, NIOSH bases its recommended exposure limits for EGBE on data from studies in animals. The data were adjusted to allow for uncertainties in the extrapolation from animals to humans. Because any effects of EGBEA are likely to occur after this compound is metabolized to EGBE, the same REL is recommended for EGBEA.

The National Institute for Occupational Safety and Health (NIOSH) therefore recommends that exposure to EGBE and EGBEA in the workplace be limited to 5 parts per million parts of air (5 ppm). Dermal contact is prohibited because EGBE and EGBEA are readily absorbed through the skin.

CONTENTS

Foreword	iii
Abstract	iv
Abbreviations	x
Acknowledgments	xii

1 RECOMMENDATIONS FOR STANDARDS	1
Section 1.1 Recommended Exposure Limits for EGBE and EGBEA	1
1.1.1 Exposure	1
1.1.2 Sampling and Analysis	1
Section 1.2 Exposure Monitoring	2
1.2.1 Industrial Hygiene Surveys	2
1.2.2 Personal Monitoring	2
1.2.3 Biological Monitoring	3
Section 1.3 Medical Monitoring	3
1.3.1 General	3
1.3.2 Preplacement Medical Examinations	3
1.3.3 Periodic Medical Examinations	4
Section 1.4 Labeling and Posting	4
1.4.1 Labeling	4
1.4.2 Posting	4
Section 1.5 Protective Clothing and Equipment	6
1.5.1 Eye and Face Protection	6
1.5.2 Skin Protection	6
1.5.3 Respiratory Protection	6
Section 1.6 Informing Workers About the Hazards of EGBE and EGBEA	10
1.6.1 Hazard Communication	10
1.6.2 Training	10
1.6.3 File of Written Hazard Information	10
Section 1.7 Engineering Controls and Work Practices	10
1.7.1 Engineering Controls	10
1.7.2 General Work Practices	11
1.7.3 Confined or Enclosed Spaces	12

1.7.4	Emergency Procedures	13
1.7.5	Storage	14
1.7.6	Waste Disposal	14
Section 1.8	Sanitation and Hygiene	14
1.8.1	Food, Cosmetics, and Tobacco	14
1.8.2	Handwashing	14
1.8.3	Laundrying	14
1.8.4	Cleanup of Work Area	14
1.8.5	Showering and Changing Facilities	15
Section 1.9	Recordkeeping	15
1.9.1	Exposure Monitoring	15
1.9.2	Medical Monitoring	15
1.9.3	Record Retention	15
1.9.4	Availability of Records	15
1.9.5	Transfer of Records	16
2	INTRODUCTION	17
2.1	Purpose	17
2.2	Scope	17
3	PROPERTIES, PRODUCTION, AND POTENTIAL FOR EXPOSURE	19
3.1	Chemical and Physical Properties	19
3.2	Production Methods and Uses	19
3.3	Number of Workers Potentially Exposed	21
4	EFFECTS OF EXPOSURE	25
4.1	Effects on Humans	25
4.1.1	Case Studies	25
4.1.2	Experimental Exposure	26
4.2	Metabolism, Uptake, and Elimination	26
4.2.1	Research Studies	26
4.2.2	Summary of Studies on Metabolism, Uptake, and Elimination	27
4.3	Effects on Animals	28
4.3.1	Acute Toxicity	28
4.3.2	Hematologic Effects	32

4.3.3	Reproductive Effects in Males	38
4.3.4	Effects on the Female Reproductive System and the Embryo	44
4.3.5	Carcinogenicity	46
4.3.6	Mutagenicity	46
4.3.7	Cytotoxicity	48
5	HAZARD IDENTIFICATION	49
5.1	Environmental Sampling	49
5.2	Analytical Methods	49
5.3	Medical Monitoring	50
5.4	Biological Monitoring	50
5.4.1	Justification for Biological Monitoring	51
5.4.2	Selection of Monitoring Medium	51
5.4.3	Limitations of Biological Monitoring	52
5.4.4	Correlation of EGBE Uptake with BAA Excretion	52
5.4.5	Assessment of Biological Monitoring Results in Various Studies	52
5.4.6	Method for Analyzing Urinary BAA	57
5.4.7	Summary	57
6	OTHER STANDARDS AND RECOMMENDATIONS	58
7	ASSESSMENT OF EFFECTS	60
7.1	Correlation of Exposure and Effects	60
7.1.1	EGBE	60
7.1.2	EGBEA	64
7.2	Basis for the Recommended Standard for EGBE and EGBEA	64
8	METHODS FOR WORKER PROTECTION	67
8.1	Informing Workers of Hazards	67
8.2	Work Practices	68
8.2.1	Worker Isolation	68
8.2.2	Storage and Handling	68
8.2.3	Sanitation and Hygiene	69
8.2.4	Spills and Waste Disposal	69

8.3	Labeling and Posting	70
8.4	Emergencies	70
8.5	Engineering Controls	71
8.6	Personal Protective Equipment	71
	8.6.1 Protective Clothing and Equipment	71
	8.6.2 Respiratory Protection	72
8.7	Chemical Substitution	73
8.8	Exposure Monitoring	73
8.9	Medical Monitoring	74
	8.9.1 General Requirements	74
	8.9.2 Medical Examinations	75
8.10	Biological Monitoring	77
8.11	Recordkeeping	77
9	RESEARCH NEEDS	78
 APPENDICES		
A	Methods for Sampling and Analysis of EGBE and EGBEA in Air	79
B	Material Safety Data Sheet	111
C	Background of Methods Used for Analysis of BAA in Urine	119
D	Guidelines for Biological Monitoring	121
E	Medical Aspects of Wearing Respirators	126
 REFERENCES		
 PUBLICATIONS EXAMINED		
		147

ABBREVIATIONS

ACGIH	American Conference of Governmental Industrial Hygienists
BAA	butoxyacetic acid
Cal OSHA	California Occupational Safety and Health Administration
CAS	Chemical Abstracts Service
cc	cubic centimeter
CFR	Code of Federal Regulations
CHO	Chinese hamster ovary
CNS	central nervous system
EAA	ethoxyacetic acid
EC ₅₀	concentration that allows 50% cell formation
EGBE	ethylene glycol monobutyl ether
EGBEA	ethylene glycol monobutyl ether acetate
EGEE	ethylene glycol monoethyl ether
EGEEA	ethylene glycol monoethyl ether acetate
FR	Federal Register
g.d.	gestation day
Hb	hemoglobin
Hct	hematocrit
i.v.	intravenous
kg	kilogram
L	liter
LC ₅₀	lethal concentration for 50% of the exposed animals
LD ₅₀	lethal dose for 50% of the exposed animals
L/min	liter per minute

EGBE and EGBEA

LOAEL	lowest observable adverse effect level
m.a.c.	maximum allowable concentration
MCHb	mean cell hemoglobin
MCHC	mean cell hemoglobin concentration
MCV	mean cell volume
mg	milligram
mg/m³	milligrams per cubic meter
mM	millimolar
mmol	millimole
MSDS	material safety data sheet
MSHA	Mine Safety and Health Administration
NFPA	National Fire Protection Association
NIOSH	National Institute for Occupational Safety and Health
NOAEL	no observable adverse effect level
NOES	National Occupational Exposure Survey
NTP	National Toxicology Program
OSHA	Occupational Safety and Health Administration
PEL	permissible exposure limit
ppm	parts per million parts of air
REL	recommended exposure limit
RBC	erythrocyte or red blood cell
RTECS	Registry of Toxic Effects of Chemical Substances
s.c.	subcutaneous
STEL	short-term exposure limit
TLV[®]	threshold limit value
TSCAPP	Toxic Substances Control Act Plant and Production
TWA	time-weighted average
UCC	Union Carbide Corporation

UDS	unscheduled DNA synthesis
μmol	micromole
USITC	United States International Trade Commission
W	watt
WBC	white blood cell

ACKNOWLEDGMENTS

This document was prepared by the staff of the Division of Standards Development and Technology Transfer, Richard W. Niemeier, Ph.D., Director. Joann Wess developed the document. The contributions of other National Institute for Occupational Safety and Health (NIOSH) personnel are gratefully acknowledged: David D. Bayse, Ph.D.; Barry R. Belinky; Stephen P. Berardinelli, Ph.D.; Nancy J. Bollinger; Paul E. Caplan; David Dankovick, Ph.D.; Rick P. Ferguson; Jerry Flesch; Bryan D. Hardin, Ph.D.; Kent Hatfield, Ph.D.; Eugene R. Kennedy, Ph.D.; Larry K. Lowry, Ph.D.; Howard Ludwig; Robert W. Mason, Ph.D.; B.K. Nelson, Ph.D.; William H. Perry; Greg M. Piacitelli; Laurence Reed; Michael Roder; David Votaw; William D. Wagner; and Ralph Zumwalde.

Ruth Grubbs and Anne Hamilton performed editorial review and coordinated production; Vanessa Becks and Susan Marksberry provided editorial assistance and produced camera-ready copy; and Judy Curless, Mattie Frei, JoAnne Hamons, Denise Hill, Susan Marksberry, and June Mefford typed the draft.

We wish to thank the following consultants for their review of this document:

Dr. Frank Mirer
Director, Health and Safety Department
United Auto Workers
8000 E. Jefferson
Detroit, Michigan 48214

Dr. Joan McCuen
ARCO Chemical Company
3801 West Chester Pike
Newtown Square, Pennsylvania 19073

Mr. Matthew Gillen,
for the AFL-CIO
Director
Worker's Institute for Safety and Health
Washington, D.C. 20036

Mr. Walter Lypka
Graphic Communications
International Union
1900 L Street, N.W.
Washington, D.C. 20036

Mr. Frank Burkhardt
for Mr. William Duval
International Brotherhood of
Builders and Allied Trades
United Unions Building
1750 New York Avenue, N.W.
Washington, D.C. 20006

Dr. H. Veulemans
Laboratorium voor arbeidshygiene
en-toxicologie
Provisorium 1, Minderbroedersstraat
17, B-3000
Leuven, Belgium

Dr. E. Marshall Johnson
Daniel Baugh Institute
Jefferson Medical College
1020 Locust Street
Philadelphia, Pennsylvania 19107

Chemical Manufacturers Association
Dr. Joseph V. Rodricks
Dr. Jeffrey S. Ferguson
Dr. Resha M. Putzrath
Mr. Matthew Fitzgerald
2501 M Street, N.W.
Washington, D.C. 20037

Dr. Laura Welch
George Washington University
Department of Medicine,
Occupational Medicine Program
6th Floor
2150 Pennsylvania Avenue, N.W.
Washington, D.C. 20039

Dr. P. Sharma
for William Kelley of ACGIH
Utah State University
College of Agriculture Toxicology
Program
Department of Animal, Dairy, and
Veterinary Sciences
Logan, Utah 84322-5600

Dr. Robert Elves
for the Department of Defense
Department of the Air Force
Harry G. Armstrong Aerospace
Medical Research Laboratory
Wright-Patterson Air Force Base
Ohio 45433-6573

Dr. Frank Welsch
Chemical Industry Institute
of Toxicology
P.O. Box 12137
Research Triangle Park
North Carolina 27709